Triple therapy shows promise for hard-to-treat liver cancer
NCT ID NCT06925516
First seen Jan 10, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests a combination of two drugs (apatinib and adebrelimab) plus chemotherapy (GEMOX) as a first treatment for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it is. About 38 adults aged 18-75 who have not had prior systemic therapy for advanced disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.